Revance Prices $100M Preapproved Offering Amid Shutdown
Biotechnology company Revance Therapeutics said on Thursday that it has priced a $100 million follow-on offering by way of a preapproved U.S. Securities and Exchange Commission filing that will allow the...To view the full article, register now.
Already a subscriber? Click here to view full article